Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Levetiracetam
Keppra
Routinely available
SMC (395/07)
09/11/2023
Indication
Adjunctive therapy in treatment of myclonic seizures in adults and adolescents from 12 years of age with juvenile muclonic epilepsy
Therapeutic Area
Central nervous system
Status Description
Routinely available
Formulation
250mg, 500mg, 750mg, 1000mg tablets and oral solution 100mg/ml
Comments
-
Link to Advice
Advice Published
11/02/2008
SMC Submission Type
Resubmission
SMC Status
Accepted